Corvus Pharmaceuticals vs Spyre Therapeutics
CRVS and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRVS and SYRE compare
Spyre Therapeutics is the larger company, worth 9.7 times as much as Corvus Pharmaceuticals ($8.3B against $856M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRVS | SYRE |
|---|---|---|
| Size and price | ||
| Market cap | $856M | $8.3B |
| Share price | $10.17 | $93.81 |
| Change, 1 year | 16.0% | 299% |
| Change, 5 years | 198% | −41.8% |
| Beta (5Y) | 0.65 | 1.99 |
| Employees | 37 | 102 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.8× (better) | 7.5× |
| FCF yield | −5.3% | – |
| Profitability | ||
| Return on equity | −35.4% | −23.0% (better) |
| Return on invested capital | −564% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 16.16 | 18.53 (better) |
| Altman Z-score | 34.46 | 68.16 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.1% | 109% |
| Held by insiders | 30.5% | 20.3% |
| Insider net buying, 12 months | $384K (better) | −$442M |
| Short interest, % of float | 30.4% | 16.5% |
Go deeper
- CRVS stock overview
- CRVS income statement
- CRVS valuation and score
- SYRE stock overview
- SYRE income statement
- SYRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.